Literature DB >> 30277295

No-touch ablation in hepatocellular carcinoma has the potential to prevent intrasubsegmental recurrence to the same degree as surgical resection.

Yusuke Kawamura1,2, Kenji Ikeda1,2, Junichi Shindoh3,2, Yuta Kobayashi3,2, Kayoko Kasuya1,2, Shunichiro Fujiyama1,2, Tetsuya Hosaka1,2, Masahiro Kobayashi1,2, Satoshi Saitoh1,2, Hitomi Sezaki1,2, Norio Akuta1,2, Fumitaka Suzuki1,2, Yoshiyuki Suzuki1,2, Yasuji Arase1,2, Masaji Hashimoto3,2, Hiromitsu Kumada1,2.   

Abstract

AIM: The aim of this study was to clarify the utility of a no-touch pincer ablation procedure that uses bipolar electrodes to prevent intrasubsegmental tumor recurrence after radiofrequency ablation (RFA) for patients with hepatocellular carcinoma (HCC) compared to surgical resection.
METHODS: We evaluated 175 consecutive patients with HCC (single nodule, tumor diameter ≤ 30 mm) who underwent surgical resection (146 received partial resection) and 313 patients who received RFA; 277 patients received touch ablation using a monopolar or bipolar RFA device, and 36 received no-touch ablation using a bipolar RFA device. Pretreatment arterial and portal phase dynamic computed tomography (CT) or magnetic resonance imaging (MRI) images were classified into four enhancement patterns: Type 1 and Type 2 are homogeneous enhancement patterns without or with increased arterial blood flow, respectively; Type 3 is a heterogeneous enhancement pattern with a septum-like structure; and Type 4 is an irregularly shaped ring structure enhancement pattern.
RESULTS: Cumulative recurrence rates significantly differed between procedures (surgical resection, 7.5%; no-touch ablation, 2.9%; and touch ablation, 17.7% at the third year; P = 0.005). Multivariate Cox proportional hazards analysis revealed that enhancement pattern type (Type 3: hazard ratio [HR], 2.95; P = 0.002; and Type 4: HR, 3.88, P = 0.002), treatment procedure (touch ablation: HR, 3.36; P < 0.001), and serum α-fetoprotein level (≥30 μg/L: HR, 1.87; P = 0.009) were significant predictors of intrasubsegmental recurrence. No significant differences between no-touch ablation and surgical resection were observed.
CONCLUSION: The no-touch pincer ablation procedure has the potential to prevent intrasubsegmental recurrence after RFA for patients with HCC to the same degree as partial resection.
© 2018 The Japan Society of Hepatology.

Entities:  

Keywords:  bipolar; hepatocellular carcinoma; multipolar; no-touch ablation; radiofrequency ablation; surgical resection

Year:  2018        PMID: 30277295     DOI: 10.1111/hepr.13254

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  7 in total

1.  Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Early Progressive Disease following Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma.

Authors:  Yusuke Kawamura; Masahiro Kobayashi; Junichi Shindoh; Masaru Matsumura; Satoshi Okubo; Nozomu Muraishi; Shunichiro Fujiyama; Tetsuya Hosaka; Satoshi Saitoh; Hitomi Sezaki; Norio Akuta; Fumitaka Suzuki; Yoshiyuki Suzuki; Kenji Ikeda; Yasuji Arase; Masaji Hashimoto; Hiromitsu Kumada
Journal:  Oncology       Date:  2022-03-01       Impact factor: 3.734

2.  Switching Monopolar No-Touch Radiofrequency Ablation Using Octopus Electrodes for Small Hepatocellular Carcinoma: A Randomized Clinical Trial.

Authors:  Sae-Jin Park; Eun Ju Cho; Jeong-Hoon Lee; Su Jong Yu; Yoon Jun Kim; Jung-Hwan Yoon; Hyo-Jin Kang; Jeong Hee Yoon; Dong Ho Lee; Se Hyung Kim; Jae Young Lee; Jeong Min Lee
Journal:  Liver Cancer       Date:  2020-12-08       Impact factor: 11.740

3.  Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Liver Fat Mass and Body Composition in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.

Authors:  Yoshitaka Arase; Koichi Shiraishi; Kazuya Anzai; Hirohiko Sato; Erika Teramura; Kota Tsuruya; Shunji Hirose; Ryuzo Deguchi; Masao Toyoda; Tetsuya Mine; Tatehiro Kagawa
Journal:  Clin Drug Investig       Date:  2019-07       Impact factor: 2.859

4.  L-Carnitine counteracts in vitro fructose-induced hepatic steatosis through targeting oxidative stress markers.

Authors:  A Montesano; P Senesi; F Vacante; G Mollica; S Benedini; M Mariotti; L Luzi; I Terruzzi
Journal:  J Endocrinol Invest       Date:  2019-11-08       Impact factor: 5.467

5.  Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria.

Authors:  Hironori Ochi; Atsushi Hiraoka; Masashi Hirooka; Yohei Koizumi; Michiko Amano; Nobuaki Azemoto; Takao Watanabe; Osamu Yoshida; Yoshio Tokumoto; Toshie Mashiba; Tomoyuki Yokota; Masanori Abe; Kojiro Michitaka; Yoichi Hiasa; Kouji Joko
Journal:  J Gastroenterol       Date:  2020-12-05       Impact factor: 7.527

6.  The impact of background liver disease on the long-term prognosis of very-early-stage HCC after ablation therapy.

Authors:  Kenta Takaura; Masayuki Kurosaki; Kento Inada; Sakura Kirino; Kouji Yamashita; Tomohiro Muto; Leona Osawa; Shuhei Sekiguchi; Yuka Hayakawa; Mayu Higuchi; Shun Kaneko; Chiaki Maeyashiki; Nobuharu Tamaki; Yutaka Yasui; Jun Itakura; Kaoru Tsuchiya; Hiroyuki Nakanishi; Yuka Takahashi; Namiki Izumi
Journal:  PLoS One       Date:  2022-02-23       Impact factor: 3.240

7.  Perivascular vital cells in the ablation center after multibipolar radiofrequency ablation in an in vivo porcine model.

Authors:  F G M Poch; C A Neizert; B Geyer; O Gemeinhardt; S M Niehues; J L Vahldiek; K K Bressem; K S Lehmann
Journal:  Sci Rep       Date:  2021-07-06       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.